{"filing":{"accession_number":"0001193125-26-335101","cik":"0001672619","ticker":"ELVN","company_name":"Enliven Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-05","report_date":"2026-08-05","primary_document":"elvn-20260805.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1672619/000119312526335101/elvn-20260805.htm"},"events":[{"id":24734,"run_id":22428,"accession_number":"0001193125-26-335101","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a clear earnings release disclosing Enliven's Q2 2026 financial results, including R\u0026D expenses ($29.0M), G\u0026A expenses ($8.2M), net loss ($32.5M), and cash position ($895.2M). The press release is attached as Exhibit 99.1 and filed under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings announcements. The disclosure includes both financial statements and operational highlights regarding the ELVN-001 clinical program.","company_name":"Enliven Therapeutics, Inc.","ticker":"ELVN","filing_date":"2026-08-05","form":"8-K","submitted_at":null,"items":[{"id":25392,"accession_number":"0001193125-26-335101","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release disclosing Enliven's Q2 2026 financial results, including R\u0026D expenses ($29.0M), G\u0026A expenses ($8.2M), net loss ($32.5M), and cash position ($895.2M). The press release is attached as Exhibit 99.1 and filed under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings announcements. The disclosure includes both financial statements and operational highlights regarding the ELVN-001 clinical program.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-07T02:17:08.985021+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":25392,"accession_number":"0001193125-26-335101","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release disclosing Enliven's Q2 2026 financial results, including R\u0026D expenses ($29.0M), G\u0026A expenses ($8.2M), net loss ($32.5M), and cash position ($895.2M). The press release is attached as Exhibit 99.1 and filed under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings announcements. The disclosure includes both financial statements and operational highlights regarding the ELVN-001 clinical program.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-07T02:17:08.985021+00:00","company_name":"Enliven Therapeutics, Inc.","ticker":"ELVN","filing_date":"2026-08-05"}]}